Related Experiment Video

Updated: May 19, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

TG4010: A therapeutic vaccine against MUC1 expressing tumors

Jean-Marc Limacher1, Elisabeth Quoix

  • 1Transgene SA; Illkirch, France.

Oncoimmunology
|August 31, 2012
PubMed

Insights

TG4010, a cancer vaccine using modified vaccinia Ankara (MVA) viral vector, is being developed for advanced non-small cell lung cancer. It is administered with chemotherapy, and biomarkers for predicting treatment effectiveness have been found.

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccinology

Background:

  • TG4010 is an advanced therapeutic cancer vaccine.
  • It utilizes a modified vaccinia Ankara (MVA) viral vector.
  • The vaccine expresses MUC1 and interleukin 2.

Purpose of the Study:

  • To evaluate TG4010 in combination with first-line chemotherapy.
  • To investigate its efficacy in patients with advanced non-small cell lung cancer.
  • To identify potential predictive biomarkers for treatment activity.

Main Methods:

  • Clinical development of TG4010.
  • Combination therapy with chemotherapy.
  • Biomarker identification and validation.

Main Results:

  • TG4010 shows promise in advanced non-small cell lung cancer.
  • Combination therapy is the focus of current clinical development.
  • Predictive biomarkers for TG4010 activity have been identified.

Conclusions:

  • TG4010 is a viable therapeutic cancer vaccine candidate.
  • Further research is warranted for advanced non-small cell lung cancer treatment.
  • Biomarkers may personalize TG4010 treatment strategies.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.